US2008027228A1PendingUtilityA1

Substituted thioacetamides

Assignee: CEPHALON INCPriority: May 15, 2001Filed: Jul 3, 2007Published: Jan 31, 2008
Est. expiryMay 15, 2021(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 9/00A61P 25/24A61P 25/28A61P 25/00A61P 25/18A61P 25/16A61P 25/20C07D 263/16C07D 213/34C07D 233/64C07D 495/04C07D 417/06C07D 263/34A61P 1/00C07D 409/14C07D 207/16C07D 211/88C07D 263/32C07D 219/04C07D 207/416C07D 277/26C07C 323/60C07D 277/56C07D 307/68C07D 333/18A61P 1/14C07D 409/12C07D 311/84C07D 413/14C07D 207/273C07D 275/02C07D 335/14C07C 317/44C07D 261/08C07C 323/63C07C 2603/18C07D 231/54A61P 11/00C07C 2603/32C07D 409/06
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.

Claims

exact text as granted — not AI-modified
1 . A method of preparing a compound of formula eee  
     
       
         
         
             
             
         
       
     
     comprising converting a compound of formula ddd  
     
       
         
         
             
             
         
       
     
     to an ester, then reacting the ester with ammonia to give the compound of formula eee;  
     wherein 
 Ar 1  and Ar 2  are each independently selected from C 6 -C 10  aryl or heteroaryl; 
 wherein each of Ar 1  or Ar 2  may be independently optionally substituted with 1-3 substituents independently selected from:  
 a) H, C 6 -C 10  aryl, heteroaryl, F, Cl, Br, I, —CN, —CF 3 , —NO 2 , —OH, —OR 7 , —O(CH 2 ) p NR 9 R 10 , —OC(═O)R 7 , —OC(═O)NR 9 R 10 , —O(CH 2 ) p OR 8 , —CH 2 OR 8 , —NR 9 R 10 , —NR 8 S(═O) 2 R 7 , —NR 8 C(═O)R 7 , or —NR 8 C(═S)R 7 ;  
 b) —CH 2 OR 11 ;  
 c) —NR 8 C(═O)NR 9 R 10 , —NR 8 C(═S)NR 9 R 10 , —CO 2 R 12 , —C(═O)R 13 , —C(═O)NR 9 R 10 , —C(═S)NR 9 R 10 , —CH═NOR 12 , —CH═NR 7 , —(CH 2 ) p NR 9 R 10 , —(CH 2 ) p NHR 11 , —CH═NNR 12 R 12A , —C(═NR 8 )NR 8A R 8B —NR 8 C(═NH)R 8A , —NR 8 C(═NH)NR 8A R 8B ,  
                     
 d) —S(O) y R 7 , —(CH 2 ) p S(O) y R 7 , —CH 2 S(O) y R 7 ; and  
 e) C 1 -C 8  alkyl, C 2 -C 8  alkenyl, or C 2 -C 8  alkynyl, where: 
 1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or  
 2) each alkyl, alkenyl or alkynyl group is independently substituted with 1 to 3 groups independently selected from C 6 -C 10  aryl, heteroaryl, F, Cl, Br, I, CF 3 , —CN, —NO 2 , —OH, —OR 7 , —CH 2 OR 8 , —NR 9 R 10 , —O—(CH 2 ) p —OH, —S—(CH 2 ) p —OH, —X 1 (CH 2 ) p OR 7 , X 1 (CH 2 ) p NR 9 R 10 , —X 1  (CH 2 ) p C(═O)NR 9 R 10 , —X 1  (CH 2 ) p C(═S)NR 9 R 10 , —X 1 (CH 2 ) p OC(═O)NR 9 R 10 , —X 1  (CH 2 ) p CO 2 R 8 , —X 1 (CH 2 ) p S(O) y R 7 , —X 1 (CH 2 ) p NR 8 C(═O)NR 9 R 10 , —C(═O)R 13 , —CO 2 R 12 , —OC(═O)R 7 , —C(═O)NR 9 R 10 , —OC(═O)NR 12 R 12A , O-tetrahydropyranyl, —C(═S)NR 9 R 10 , —CH═NNR 12 R 12A , —CH═NOR 12 , —CH═NR 7 , —CH═NNHCH(N═NH)NH 2 , —NR 8 CO 2 R 7 , —NR 8 C(═O)NR 9 R 10 , —NR 8 C(═S)NR 9 R 10 , —NHC(═NH)NH 2 , —NR 8 C(═O)R 7 , —NR 8 C(═S)R 7 , —NR 8 S(═O) 2 R 7 , —S(O) y R 7 , —S(═O) 2 NR 12 R 12A , —P(═O)(OR 8 ) 2 , —OR 11 , and a C 5 -C 7  monosaccharide where each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, C 1 -C 4  alkyl, C 1 -C 4  alkoxy, or —O—C(═O)R 7 ;  
 
 
 X 1  is —O—, —S—, —N(R 8 )—;  
 R 7  is C 1 -C 6  alkyl, C 6 -C 10  aryl, or heteroaryl;  
 R 8 , R 8A  and R 8B  are each independently H, C 1 -C 4  alkyl, or C 6 -C 10  aryl;  
 R 9  and R 10  are independently selected from H, C 1 -C 4  alkyl, and C 6 -C 10  aryl; or R 9  and R 10  together with the nitrogen to which they are attached, form a 3-7 member heterocyclic ring;  
 R 11  is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;  
 R 12  and R 12A  are each independently selected from H, C 1 -C 6  alkyl, cycloalkyl, C 6 -C 10  aryl, and heteroaryl; or R 12  and R 12A , together with the nitrogen to which they are attached, form a 5-7 member heterocyclic ring;  
 R 13  is H, C 1 -C 6  alkyl, cycloalkyl, C 6 -C 10  aryl, heteroaryl, —C(═O)R 7 , —C(═O)NR 9 R 10 , or —C(═S)NR 9 R 10 ;  
 m is 0, 1, 2 or 3;  
 p is 1, 2, 3, or 4;  
 t is 2, 3, or 4;  
 y is 0, 1 or 2;  
 or the stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt or ester forms thereof.  
 
   
   
       2 . The method of  claim 1 , wherein m is 1.  
   
   
       3 . The method of  claim 1 , wherein Ar 1  and Ar 2  are each independently selected from a five or six membered heteroaryl comprising 1-3 atoms of —N—, —O—, or —S—.  
   
   
       4 . The method of  claim 3 , wherein Ar 1  and Ar 2  are 3-thienyl.  
   
   
       5 . The method of  claim 1 , wherein Ar 1  is phenyl and Ar 2  is a five or six membered heteroaryl comprising 1-3 atoms of —N—, —O—, or —S—.  
   
   
       6 . The method of  claim 1 , wherein Ar 1  and Ar 2  are each independently selected from phenyl, thienyl, isothiazolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl, and imidazolyl.  
   
   
       7 . The method of  claim 6 , wherein Ar 1  and Ar 2  are phenyl.  
   
   
       8 . The method of  claim 7 , wherein m is 1.

Join the waitlist — get patent alerts

Track US2008027228A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.